Two active federal MDLs now define the current federal picture
The April 1, 2026 JPML report shows two GLP-1 product-liability MDLs that matter right now. MDL 3094 covers the larger GI-injury track, while MDL 3163 is the separate NAION vision-loss track.
That split matters for content and for screening. GI and sudden-vision-loss claims should not be blended into one generic page or one generic intake bucket because the medical facts, records, experts, and litigation theories are different.
What changed in 2026
The most important 2026 regulatory shift so far is FDA's January 13, 2026 request to remove suicidal-behavior and ideation language from obesity GLP-1 labels after the agency found no increased risk. That makes the mental-health topic much weaker than it looked in older screenshots or older label versions.
The current February 2026 Wegovy label also matters because it still gives the clearest public framework for severe GI reactions, pregnancy timing, diabetic retinopathy monitoring, and the thyroid boxed warning. It is the label version used throughout this site, rather than older 2024 or 2025 PDFs.
What firms often ask about first
A useful public example is Levin Papantonio's GLP-1 intake criteria sheet. That public document screens heavily for brand-name drug use, a qualifying diagnosis, timing close to drug use, ER or hospital treatment, and whether the person already has a lawyer.
That does not mean every firm uses the same checklist. It does show the general shape of a more complete inquiry: brand-name product, objective diagnosis, clear timing, significant treatment, and records that tie the event together.
Which research and trials are worth watching now
The research topics that matter most right now are severe GI injury, gastric retention, and NAION. FDA and JPML materials, ophthalmology research, and newer gastric-retention studies all help show where the evidence is moving.
ClinicalTrials.gov listings on gastric contents, semaglutide-induced gastric retention, and reproductive or IVF questions are also worth watching because even when they are not lawsuit studies, they can still change the public evidence base around the drug class.